Hantz Financial Services’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $108K | Buy |
713
+24
| +3% | +$3.64K | ﹤0.01% | 744 |
|
|
2025
Q1 | $104K | Sell |
689
-134
| -16% | -$20.2K | ﹤0.01% | 620 |
|
|
2024
Q4 | $152K | Sell |
823
-35,834
| -98% | -$6.62M | ﹤0.01% | 578 |
|
|
2024
Q3 | $7.22M | Sell |
36,657
-1,440
| -4% | -$284K | 0.13% | 178 |
|
|
2024
Q2 | $7.87M | Sell |
38,097
-1,640
| -4% | -$339K | 0.15% | 162 |
|
|
2024
Q1 | $10.8M | Sell |
39,737
-2,187
| -5% | -$593K | 0.21% | 130 |
|
|
2023
Q4 | $9.91M | Sell |
41,924
-3,208
| -7% | -$758K | 0.22% | 138 |
|
|
2023
Q3 | $8.85M | Buy |
45,132
+35
| +0.1% | +$6.86K | 0.22% | 135 |
|
|
2023
Q2 | $9.48M | Buy |
45,097
+463
| +1% | +$97.3K | 0.24% | 128 |
|
|
2023
Q1 | $9.01M | Buy |
44,634
+1,335
| +3% | +$269K | 0.25% | 130 |
|
|
2022
Q4 | $9.44M | Buy |
43,299
+1,361
| +3% | +$297K | 0.28% | 116 |
|
|
2022
Q3 | $8.25M | Sell |
41,938
-3,202
| -7% | -$630K | 0.29% | 109 |
|
|
2022
Q2 | $9.66M | Buy |
45,140
+1,193
| +3% | +$255K | 0.33% | 98 |
|
|
2022
Q1 | $12.5M | Sell |
43,947
-9,333
| -18% | -$2.65M | 0.37% | 79 |
|
|
2021
Q4 | $20.1M | Buy |
53,280
+3,312
| +7% | +$1.25M | 0.58% | 39 |
|
|
2021
Q3 | $20.6M | Buy |
49,968
+7,009
| +16% | +$2.89M | 0.68% | 33 |
|
|
2021
Q2 | $15.9M | Buy |
42,959
+2,654
| +7% | +$982K | 0.58% | 38 |
|
|
2021
Q1 | $11.7M | Buy |
40,305
+1,415
| +4% | +$410K | 0.48% | 45 |
|
|
2020
Q4 | $9.72M | Buy |
38,890
+137
| +0.4% | +$34.2K | 0.43% | 59 |
|
|
2020
Q3 | $8.78M | Buy |
38,753
+40
| +0.1% | +$9.06K | 0.45% | 55 |
|
|
2020
Q2 | $6.75M | Buy |
38,713
+896
| +2% | +$156K | 0.38% | 68 |
|
|
2020
Q1 | $4.77M | Buy |
+37,817
| New | +$4.77M | 0.33% | 85 |
|